用新型抗肿瘤药物RA - 700治疗后小鼠出现白细胞增多症。
Leukocytosis in mice following therapy with a novel antitumor agent, RA-700.
作者信息
Kato T, Suzumura Y, Liu F Z, Tateno H, Ogiu T, Ota K
机构信息
Laboratory of Chemotherapy, Aichi Cancer Center, Nagoya, Japan.
出版信息
Jpn J Cancer Res. 1989 Mar;80(3):290-3. doi: 10.1111/j.1349-7006.1989.tb02307.x.
Nine daily intravenous (iv) injections of RA-700 (an antitumor cyclic hexapeptide) at doses of 2 to 6 mg/kg/day caused increases of WBC counts at 4-6 days after treatment in normal C57BL/6 X DBA/2 (BDF1) mice. The percentages of neutrophils and lymphocytes were modified. There was a decrease of colony-forming units in culture (CFUc) in bone marrow to 40% of the control value on day 1 but CFUc rapidly returned to normal values on day 3. The colony-forming units in spleen (CFUs) in bone marrow decreased during treatment. On the other hand, CFUc and CFUs in spleen were increased from the initiation of treatment to the time prior to the increase of WBC count. Spleen weight increased after treatment, and histologically, increases of immature and also mature granulocytes and megakaryocytes were observed. However, RA-700 did not stimulate the progress of hematoprogenitors in vitro. The results indicated that RA-700 stimulates the progress of hematoprogenitors in the spleen, but this effect is probably indirect.
对正常的C57BL/6×DBA/2（BDF1）小鼠，每天静脉注射9次剂量为2至6毫克/千克/天的RA-700（一种抗肿瘤环六肽），会导致治疗后4至6天白细胞计数增加。中性粒细胞和淋巴细胞的百分比发生了改变。骨髓中培养的集落形成单位（CFUc）在第1天降至对照值的40%，但CFUc在第3天迅速恢复到正常水平。治疗期间骨髓中脾脏集落形成单位（CFUs）减少。另一方面，从治疗开始到白细胞计数增加之前，脾脏中的CFUc和CFUs增加。治疗后脾脏重量增加，组织学检查显示未成熟以及成熟的粒细胞和巨核细胞增多。然而，RA-700在体外并未刺激造血祖细胞的增殖。结果表明，RA-700刺激脾脏中造血祖细胞的增殖，但这种作用可能是间接的。
Zotero 插件